Also trades as: JNJ.DE (XETRA) · $vol 1M · JNJ.SW (SIX) · $vol 0M

$256.03

-2.63 (-1.02%)

Weekly Expected Move ±2.0%

$246 $251 $256 $261 $266

NYSE · Healthcare · Drug Manufacturers - General · Tech Score Sell · Power 52 · $617.0B mcap · 2.41B float · 0.311% daily turnover · Short 50% of daily vol

Revenue Segmentation

By Product / Service

By Geography

Revenue by Segment (5-Year Trend)

Income Trends

Revenue

$94.2B +6.0% ▲

5Y CAGR: +2.7%

Gross Profit

$68.6B +11.7% ▲

5Y CAGR: +4.8%

Operating Income

$25.6B +15.6% ▲

5Y CAGR: +5.3%

Net Income

$26.8B +90.6% ▲

5Y CAGR: +12.7%

EPS (Diluted)

$11.03 +90.5% ▲

5Y CAGR: +14.9%

EBITDA

$39.9B +61.0% ▲

5Y CAGR: +10.8%

Profit Margins

Year-over-Year Growth

View Full Income Statement

Line Item	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$78.7B	$80.0B	$85.2B	$88.8B	$94.2B
YoY Growth	-4.7%	+1.6%	+6.5%	+4.3%	+6.0%
Cost of Revenue	$23.4B	$24.6B	$26.6B	$27.5B	$25.6B
Gross Profit	$55.3B	$55.4B	$58.6B	$61.4B	$68.6B
Gross Margin	70.3%	69.3%	68.8%	69.1%	72.8%
R&D Expenses	$14.3B	$14.1B	$15.1B	$17.2B	$14.7B
SG&A Expenses	$20.1B	$20.2B	$20.1B	$22.0B	$23.7B
Operating Expenses	$34.4B	$34.4B	$35.2B	$39.2B	$43.0B
Operating Income	$20.9B	$21.0B	$23.4B	$22.1B	$25.6B
Operating Margin	26.6%	26.3%	27.5%	24.9%	27.2%
Interest Expense	$183M	$276M	$772M	$755M	$971M
Income Before Tax	$19.2B	$19.4B	$15.1B	$16.7B	$32.6B
Tax Expense	$1.4B	$3.0B	$1.7B	$2.6B	$5.8B
Net Income	$20.9B	$17.9B	$35.2B	$14.1B	$26.8B
Net Margin	26.5%	22.4%	41.3%	15.8%	28.5%
EPS (Diluted)	$7.81	$6.73	$13.72	$5.79	$11.03
EBITDA	$26.8B	$26.6B	$23.3B	$24.8B	$39.9B
Shares Outstanding	2.67B	2.66B	2.56B	2.43B	2.43B

Line Item	FY2024 Q3	FY2024 Q4	FY2025 Q1	FY2025 Q2	FY2025 Q3	FY2025 Q4	FY2026 Q1	FY2026 Q2
Revenue	$22.5B	$22.5B	$21.9B	$23.7B	$24.0B	$24.6B	$24.1B	$25.3B
Cost of Revenue	$7.0B	$7.1B	$7.4B	$7.6B	$7.3B	$8.0B	$8.1B	$8.1B
Gross Profit	$15.5B	$15.4B	$14.5B	$16.1B	$16.7B	$16.6B	$16.0B	$17.3B
Gross Margin	69.0%	68.3%	66.4%	67.9%	69.6%	67.6%	66.3%	68.2%
R&D Expenses	$5.0B	$5.3B	$3.2B	$3.5B	$3.7B	$4.3B	$3.5B	$3.7B
SG&A Expenses	$5.3B	$6.3B	$5.0B	$5.8B	$5.9B	$6.8B	$6.0B	$6.4B
Operating Expenses	$10.2B	$11.6B	$8.2B	$9.3B	$9.6B	$11.0B	$9.6B	$10.1B
Operating Income	$5.3B	$3.8B	$6.3B	$6.8B	$7.1B	$5.6B	$6.4B	$7.2B
Operating Margin	23.5%	17.1%	28.8%	28.7%	29.6%	22.8%	26.6%	28.3%
Interest Expense	$193M	$137M	$204M	$308M	$18M	$214M	$272M	$281M
Income Before Tax	$3.3B	$3.9B	$13.6B	$6.5B	$7.5B	$5.0B	$6.0B	$6.7B
Tax Expense	$644M	$456M	$2.6B	$954M	$2.3B	-$150M	$755M	$1.2B
Net Income	$2.7B	$3.4B	$11.0B	$5.5B	$5.2B	$5.1B	$5.2B	$5.5B
Net Margin	12.0%	15.2%	50.2%	23.3%	21.5%	20.8%	21.8%	21.9%
EPS (Diluted)	$1.11	$1.41	$4.54	$2.29	$2.12	$2.10	$2.14	$2.27
EBITDA	$5.4B	$5.9B	$15.6B	$8.7B	$9.3B	$7.2B	$8.3B	$9.0B
Shares Outstanding	2.43B	2.43B	2.42B	2.42B	2.43B	2.44B	2.45B	2.44B

JNJ NYSE